

To: Members of the Governing Board

From: Jonathan Y. Thomas, Chair, and Art Torres, Vice Chair

Re: Appointments to the AAWG

As you know, Proposition 14 created the Treatments and Cures Accessibility and Affordability Working Group (AAWG) to recommend policies and programs to the Board to enhance access to, and the affordability of, treatments and cures arising from CIRM-funded research for California patients. The AAWG is composed of 17 members: seven members of the Board, including the Chair and Vice Chair, and 10 outside experts. Pursuant to Health & Safety Code section 125290.75, the Chair and Vice Chair of the Board are required to nominate members of the AAWG for approval by the Board. To date, the Board has appointed the following Board members to the AAWG: Dan Bernal, Allison Brashear, David Higgins, Adrianna Padilla, and Al Rowlett. In addition, the Board appointed James DeBenedetti, the Director of Plan Management at Covered California, who fills the seat for an expert in California's public insurance program and Dana Dornsife, the founder of Lazerex Cancer Foundation, who fills the seat for representative from a philanthropic organization who has experience assisting patients with clinical trial access and affordability, or with access to, and the affordability of, innovative therapies.

We now wish to nominate Dana Goldman, Interim Dean of the USC Sol Price School of Public Policy, where he holds the Leonard Schaeffer Chair and is a Distinguished Professor of Public Policy, Pharmacy, and Economics, to fill the seat for a health care economist, with experience in advising or negotiating with private insurers, government insurers, or corporate self-insurance programs on coverage for innovative therapies or human trials, including experience in assisting hospitals and clinics in covering financial gaps in coverage of the direct and indirect costs of innovative therapies. A copy of Mr. Goldman's CV is attached.



Dana P. Goldman, Ph.D.

Dana Goldman is the Leonard D. Schaeffer Chair and Distinguished Professor of Pharmacy, Public Policy, and Economics at the University of Southern California. Dr. Goldman is also the interim dean of USC's Sol Price School of Public Policy. Since inception, he has led USC's <u>Schaeffer Center for Health Policy and Economics</u>, one of the nation's premier health policy programs.

He is the author of more than 300 articles in medicine, health policy, economics, and statistics. He has served as a health policy advisor to the Congressional Budget Office, Covered California, Fred Hutchinson Cancer Institute, and National Institutes of Health. Dr. Goldman has advised many companies in the life sciences industry and currently serves on the scientific advisory board of GRAIL. He is a founding editor of the *Forum for Health Economics and Policy* and serves on several editorial boards including *Health Affairs* and the *American Journal of Managed Care*. He is a former director of the International Society for Pharmacoeconomics and Outcomes Research and the American Society of Health Economists. Dr. Goldman pioneered a "Netflix model" to improve access to prescription drugs and the value of reduced copayments for the chronically ill. His research and opinion pieces have appeared in the New York Times, Wall Street Journal, Washington Post, Stat, Forbes, Business Week, U.S. News & World Report, The Economist, Modern Healthcare, NBC Nightly News, PBS NewsHour, CNN, NPR, and other media.

Dr. Goldman is an elected member of the National Academy of Medicine and the National Academy of Social Insurance. In 2016, he was appointed a Distinguished Professor at the University of Southern California in honor of accomplishments bringing the University "special renown." He received the MetLife Foundation Silver Scholar Award in honor of his research to value healthy aging and medical innovations; the Eugene Garfield Economic Impact Prize, recognizing outstanding work demonstrating how medical research impacts the economy; the National Institute for Health Care Management Research Foundation award for excellence in health policy; and the Alice S. Hersh New Investigator Award recognizing contributions of a young scholar to health services research.

Dr. Goldman is a <u>nonresident senior fellow at The Brookings Institution</u> and research associate with the <u>National Bureau for Economic Research</u>. He also spent 15 years at RAND Corporation, where he held the Distinguished Chair in Health Economics and served as director of its health economics program and the Bing Center. He received his B.A. *summa cum laude* from Cornell University and a Ph.D. in Economics from Stanford University.